This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FSDC vs. LGND, MIRM, BHC, SDGR, AAPG, BLTE, NAMS, JANX, SUPN, and ARWRShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Ligand Pharmaceuticals (LGND), Mirum Pharmaceuticals (MIRM), Bausch Health Companies (BHC), Schrödinger (SDGR), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), NewAmsterdam Pharma (NAMS), Janux Therapeutics (JANX), Supernus Pharmaceuticals (SUPN), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "medical" sector. FS Development vs. Ligand Pharmaceuticals Mirum Pharmaceuticals Bausch Health Companies Schrödinger Ascentage Pharma Group International Belite Bio NewAmsterdam Pharma Janux Therapeutics Supernus Pharmaceuticals Arrowhead Pharmaceuticals FS Development (NASDAQ:FSDC) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking. Does the media favor FSDC or LGND? In the previous week, Ligand Pharmaceuticals had 8 more articles in the media than FS Development. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 0 mentions for FS Development. Ligand Pharmaceuticals' average media sentiment score of 1.09 beat FS Development's score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment FS Development Neutral Ligand Pharmaceuticals Positive Does the MarketBeat Community believe in FSDC or LGND? Ligand Pharmaceuticals received 553 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformFS DevelopmentN/AN/ALigand PharmaceuticalsOutperform Votes55370.45% Underperform Votes23229.55% Which has higher earnings and valuation, FSDC or LGND? Ligand Pharmaceuticals has higher revenue and earnings than FS Development. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFS DevelopmentN/AN/AN/AN/AN/ALigand Pharmaceuticals$167.13M12.62$52.15M-$0.16-683.69 Do analysts prefer FSDC or LGND? Ligand Pharmaceuticals has a consensus target price of $146.43, indicating a potential upside of 33.86%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in FSDC or LGND? 89.8% of FS Development shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.9% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is FSDC or LGND more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to FS Development's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 4.95% beat FS Development's return on equity.Company Net Margins Return on Equity Return on Assets FS DevelopmentN/A N/A N/A Ligand Pharmaceuticals 29.68%4.95%4.39% SummaryLigand Pharmaceuticals beats FS Development on 12 of the 12 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$621.80M$6.84B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E RatioN/A7.4422.6818.83Price / SalesN/A257.63404.28106.72Price / CashN/A65.8538.1834.62Price / BookN/A6.576.794.33Net IncomeN/A$143.14M$3.22B$247.97M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$49.68+0.5%N/A+73.2%$621.80MN/A0.00N/ALGNDLigand Pharmaceuticals4.4234 of 5 stars$106.47+1.6%$146.43+37.5%+52.8%$2.05B$167.13M42.4280Upcoming EarningsPositive NewsMIRMMirum Pharmaceuticals4.2746 of 5 stars$39.43+2.7%$58.20+47.6%+68.8%$1.95B$336.89M-19.52140Upcoming EarningsPositive NewsBHCBausch Health Companies4.1979 of 5 stars$5.20+10.1%$7.17+38.0%-39.5%$1.91B$9.63B-43.2919,900Analyst UpgradeSDGRSchrödinger2.4957 of 5 stars$25.99-0.8%$33.00+27.0%-1.5%$1.90B$207.54M-11.11790AAPGAscentage Pharma Group InternationalN/A$21.60+13.0%N/AN/A$1.88B$980.65M0.00600BLTEBelite Bio2.9922 of 5 stars$58.38+6.7%$96.67+65.6%+50.9%$1.86BN/A-52.5910News CoveragePositive NewsNAMSNewAmsterdam Pharma3.1874 of 5 stars$16.79+3.3%$43.33+158.1%-8.8%$1.84B$45.56M-6.464Positive NewsJANXJanux Therapeutics3.037 of 5 stars$30.01+2.4%$95.25+217.4%-44.9%$1.77B$10.59M-25.6530Upcoming EarningsNews CoveragePositive NewsSUPNSupernus Pharmaceuticals2.2776 of 5 stars$30.84+1.8%$36.00+16.7%+7.9%$1.72B$661.82M28.82580Upcoming EarningsPositive NewsARWRArrowhead Pharmaceuticals3.6192 of 5 stars$12.36+2.3%$41.44+235.3%-39.4%$1.70B$2.50M-2.39400Positive News Related Companies and Tools Related Companies Ligand Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Bausch Health Companies Competitors Schrödinger Competitors Ascentage Pharma Group International Competitors Belite Bio Competitors NewAmsterdam Pharma Competitors Janux Therapeutics Competitors Supernus Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FSDC Stock Free FSDC Stock Alerts